Objectives: The primary objective of this study was to compare a traditional green KTP laser to a new investigational yellow laser (PhotoLase) in the treatment of facial telangiectasia in terms of the treatment outcomes. The secondary objective was to assess the functionality and reliability of the PhotoLase system from the perspective of the user.
Introduction: Several lasers are used for vascular indications, but the standard lasers are yellow pulsed dye laser (585- or 595-nm) and green potassium titanyl-phosphate (KTP) laser (532-nm), because their wavelengths are close to the absorption peaks (542 and 577 nm) of oxyhaemoglobin. To address the needs of the dermatologic community a novel laser technology, namely optically pumped semiconductor disk laser (SDL), has emerged to provide a compact and cost-effective alternative for a yellow laser source.
Materials / method: The study was a randomized split-face double-blinded study that compared the treatment efficacy of the 532-nm KTP laser and the investigational 585-nm PhotoLase laser. One or two treatments were given based on the response of the first treatment. The improvement of telangiectasia was graded according to a 7-point Telangiectasia Grading Scale (TGS) by the subjects and blinded physicians. The subjects assessed the amount of pain during the treatments using Visual Analogue Scale (VAS), and evaluated adverse effects 2–3 days after the treatment(s) using a self-assessment form.
Results: At least 50% improvement was seen in 15/18 subjects after the first PhotoLase treatment, and a similar result was observed for KTP. There was no difference in the frequency of erythema, crusting or purpura between the devices, but less edema was seen after PhotoLase treatment (p<0.05). Treatment with PhotoLase was evaluated to be 4.7-fold faster than with KTP and the PhotoLase system was more compact, narrower, lighter, and easier to carry than KTP.
Conclusion: The investigational PhotoLase laser enables significantly faster treatments, providing a similar clinical outcome in the treatment of facial telangiectasia.
利益冲突声明
您有否接受任何资金来支持研究这个主题？
否
您是否接受过关于这项研究的任何酬金或其他报酬？
否
你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否
你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
